IGC Pharma, Inc. (NYSEAM: IGC)
Health Care · Pharmaceuticals · US
$0.30
-1.23% today · -17.5% 1Y
IGC Pharma, Inc. (NYSEAM: IGC) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $31.84M and employs 70 people.
Over the last twelve months the share price has lost 17.5%, trading between 0.24 and 0.50.
Tweenvest scores IGC Pharma, Inc. across four factors: quality 19/100, value 47/100, growth 0/100. Its strongest factor is value.
IGC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $31.84M
- Revenue (TTM)
- $1.11M
- P/E
- —
- EPS
- -0.08
- Dividend yield
- —
- Beta (5Y)
- 0.46
- 52-week high
- $0.50
- 52-week low
- $0.24
- Avg volume (3M)
- —
- Shares outstanding
- 103.38M
- Employees
- 70
- Next earnings
- —
About IGC Pharma, Inc.
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
- ISIN
- US45408X3089
- Founded
- 2005
- Listed since
- May 24, 2006
- Exchange
- NYSE American LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,226.58 | -0.57% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $271.58 | -0.57% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.68 | -1.77% |
| Roche Holding AGSWX: ROP | $371.62B | CHF369.70 | -1.10% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.92 | -1.47% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.35 | -0.77% |
Figures last refreshed Aug 18, 2026.